160 related articles for article (PubMed ID: 14638976)
1. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients.
Pachner AR
Neurology; 2003 Nov; 61(10):1444-6. PubMed ID: 14638976
[TBL] [Abstract][Full Text] [Related]
2. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.
Gilli F; Hoffmann F; Sala A; Marnetto F; Caldano M; Valentino P; Kappos L; Bertolotto A; Lindberg RL
Mult Scler; 2006 Dec; 12(6):738-46. PubMed ID: 17263001
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
Massart C; Gibassier J; Oger J; Le Page E; Edan G
Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
[TBL] [Abstract][Full Text] [Related]
4. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
Pachner AR; Dail D; Pak E; Narayan K
J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
[TBL] [Abstract][Full Text] [Related]
5. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Deisenhammer F; Schellekens H; Bertolotto A
J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
[TBL] [Abstract][Full Text] [Related]
6. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.
Pachner AR; Oger J; Palace J
Neurology; 2003 Nov; 61(9 Suppl 5):S18-20. PubMed ID: 14610105
[No Abstract] [Full Text] [Related]
7. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
Khan OA; Dhib-Jalbut SS
Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta.
Lapé Nixon M; Matud J; Yeh C; Prince HE
J Neuroimmunol; 2009 May; 210(1-2):104-7. PubMed ID: 19345423
[TBL] [Abstract][Full Text] [Related]
10. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
Malucchi S; Gilli F; Caldano M; Sala A; Capobianco M; di Sapio A; Granieri L; Bertolotto A
J Neurol; 2011 May; 258(5):895-903. PubMed ID: 21153733
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis.
Vartanian TK; Zamvil SS; Fox E; Sorensen PS
Neurology; 2004 Dec; 63(11 Suppl 5):S42-9. PubMed ID: 15596736
[TBL] [Abstract][Full Text] [Related]
12. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
[TBL] [Abstract][Full Text] [Related]
14. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
Prince HE; Lapé-Nixon M; Audette C; Van Horn K
J Neuroimmunol; 2007 Oct; 190(1-2):165-9. PubMed ID: 17889376
[TBL] [Abstract][Full Text] [Related]
15. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies.
Giovannoni G
Neurology; 2003 Nov; 61(9 Suppl 5):S13-7. PubMed ID: 14610104
[TBL] [Abstract][Full Text] [Related]
16. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
17. Measurement of antibodies to interferon beta in patients with multiple sclerosis.
Pachner AR
Arch Neurol; 2001 Aug; 58(8):1299-300. PubMed ID: 11493174
[No Abstract] [Full Text] [Related]
18. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.
Pachner A; Narayan K; Price N; Hurd M; Dail D
Mol Diagn; 2003; 7(1):17-25. PubMed ID: 14529316
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
[TBL] [Abstract][Full Text] [Related]
20. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
Cook SD; Quinless JR; Jotkowitz A; Beaton P;
Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
